Information  X 
Enter a valid email address

LiDCO Group Plc (LID)

  Print      Mail a friend       Annual reports

Thursday 15 August, 2019

LiDCO Group Plc

Appointment of Non-Executive Director

RNS Number : 1078J
LiDCO Group Plc
15 August 2019

LiDCO Group Plc

("LiDCO" or the "Company")


Appointment of Non-Executive Director


LiDCO (AIM: LID), the hemodynamic monitoring company, announces the appointment of James G. Wetrich to the Board, as a Non-Executive Director, with immediate effect.


James brings with him over 35 years of experience in the US healthcare industry having worked both in the medical device and healthcare provider sectors, including companies such as Abbott Laboratories, Molnlycke Healthcare, Premier Inc, and Providence Health & Services.  In the mid-1980s, James played an instrumental role in the formation of the University HealthSystem Consortium, now part of Vizient. This extensive work in the US healthcare supply chain has resulted in expert knowledge of the purchasing cycle including value analysis, strategic sourcing, supply chain relationship building and procurement logistics.


Commenting on the appointment, Matt Sassone, Chief Executive Officer of LiDCO, said: "The US represents the greatest opportunity for LiDCO's future growth. James' breadth of industry knowledge, contacts and experience in the US market brings to the Board additional skills to take Company forward."


For further information, please contact:


LiDCO Group Plc

Matt Sassone (CEO)

Tel: +44 (0)20 7749 1500

Tim Hall (CFO)


Tel: +44 (0)20 7600 1658

Geoff Nash / Hannah Boros (Corporate Finance)

Andrew Burdis (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303


Mr Wetrich (James Gleason), aged 62, currently holds or has held the following directorships and partnerships over the last five years.


Current directorships

Past directorships held within the last 5 years

Georgia Symphony Orchestra

Optomeditech Oy

Movi Medical

Brain Injury Association

Anewmed Corporation

Vevanto LLC

Reapplix Inc

Debra of America


During James Wetrich's tenure as a director, Optomeditech Oy filed for voluntary bankruptcy in Finnish Court in November 2018, proceedings were resolved in July 2019.


Except as disclosed in this announcement, neither the Company nor Mr. Wetrich are aware of any further disclosures that are required in respect of the appointment of Mr. Wetrich under Rule 17 or paragraph (g) of Schedule Two of the AIM Rules for Companies.

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.


About LiDCO Group Plc (

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 


Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.


Key Products:


LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.


LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).


LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:


·    early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·    quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time


The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 


LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.


*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.


LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 


LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.


LiDCO's headquarters are in London and its shares are traded on AIM.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t